A Phase 4 Two Dose Level Study of Naglazyme(TM) (Galsulfase) in Infants With MPS VI

Mise à jour : Il y a 4 ans
Référence : NCT00299000

Femme et Homme

Extrait

The purpose of the study is to evaluate the safety and efficacy of two dose levels of Naglazyme in infants under the age of one year who have MPS VI by monitoring physical appearance, x-ray of the skeletal system and growth.


Critère d'inclusion

  • Mucopolysaccharidosis VI ,Maroteaux Lamy Syndrome

Liens